Over the past 45 years, Mr. Gorlin has founded several biotechnology and pharmaceutical companies, including Hycor Biomedical, Inc. (acquired by Agilent), Theragenics Corporation (NYSE: TGX), CytRx Corporation (NASDAQ: CYTR), Medicis Pharmaceutical Corporation (sold to Valeant for approximately $2.6 billion), EntreMed, Inc. (NASDAQ: ENMD), MRI Interventions (MRIC), DARA BioSciences, Inc. (NASDAQ: DARA), MiMedx (NASDAQ: MDXG), and Medivation, Inc. (NASDAQ: MDVN). Mr. Gorlin served for many years on the Business Advisory Council to the Johns Hopkins School of Medicine and on The Johns Hopkins BioMedical Engineering Advisory Board and serves on the Board of Andrews Institute. Mr. Gorlin founded a number of nonmedical related companies, including Perma-Fix, Inc., Pretty Good Privacy, Inc. (sold to Network Associates), Judicial Correction Services, Inc. (sold to Correctional Healthcare), and NTC China. He started The Touch Foundation, a nonprofit organization for the blind and was a principal financial contributor to the founding of Camp Kudzu for diabetic children. He presently serves as Vice Chairman of NantKwest, Inc., Chairman of ViCapsys, CEO of Nantibody Fc and on the Boards of Medovex, Inc. (MDVXU), Catasys, Inc. (CATS), Nantibody Fc and on the Board of NTC China, Inc. He is also a member of the Research Institute Advisory Council (RIAC) at Massachusetts General Hospital.
Stephen J. McCormack, PhD
Managing Partner, Chief Scientific Officer
Dr. McCormack is a serial entrepreneur, and chief executive in the biotechnology and medical device field. He contributed to the development of several medical products and technologies that address unmet medical need. Over the past 20 years, McCormack co-founded and operated several companies including AlleCure, conducting the first clinical studies of intralymphatic immunotherapy, MannKind (NASDAQ:MNKD) with global IND trials in diabetes, cancer vaccines, and allergy. He was part of the founding of CytoMx Therapeutics (NASDAQ: CTMX) developing antibody therapeutics in oncology. He is a member of the Board of Directors of Treatment Research Institute, was previously a Trustee at The Betty Ford Center. He is a member of the President’s Advisory Council of The Albany College of Pharmacy and Health Sciences and is Chairman of the Board of Directors and CEO of Visus Technology. He lived in Europe for four years and was a Managing Director at Global Life Science Ventures in Zug, Switzerland and the Chief Executive Officer of Intelligent Medical Implants (now Pixium Vision, EUR:PIX) leading the CE mark approval across Europe for a retinal prosthetic implant to treat retinitis pigmentosa patients. He currently is currently Chief Scientific Officer of Gorlin Companies as a member of the investment team. McCormack is Chief Executive Officer of ViCapsys, Inc. a company focused on islet cell transplant for the treatment of diabetes. In addition, he is Chief Executive Officer of Aperisys, Inc., a start-up company developing immune activator drugs, vaccines and antibodies for the treatment of cancer.
Jesse Crowne has over 20 years of experience working with rapidly growing health care companies. Most recently, Jesse served as CEO of Arapeen Medical in Salt Lake City, a pre-clinical medical device company focused on developing a magnetic resonance guided focused ultrasound device for the treatment of hypertension, and as VP of Business Development for Medovex Corporation in Atlanta, GA, a clinical stage device company focused on building multiple sales channels in the orthopedic device arena. Prior to Arapeen Medical and Medovex, Mr. Crowne was an Associate with White Pine Medical, a private equity investment vehicle and subsidiary of Essex Woodlands, focused on the medical device sector.
Mr. Crowne received an MBA and an MPH from Westminster College and BS degrees in Biology and Economics from the University of Utah.
Ashley G. Johnson
Over the past 14 years, Mrs. Ashley Johnson, has been instrumental in the successful launches of numerous Gorlin Companies business ventures, including Dara Biosciences, Medivation, MiMedx, Medovex and others. Mrs. Johnson is involved in several charitable organizations including Alaqua Animal Refuge and The Zika Foundation.
Elena Ulansky has over the course of her career worked for investment companies in different capacities focused on capital raising, originating deals for PE opportunities and cross border M&A. At the Gorlin Companies she assists Steve Gorlin in managing his current investments as well as charitable activities, including The Zika Foundation.
Ms. Ulansky previously worked as a Managing Director at a New York based hedge fund with nearly US $2 billion AUM. She was responsible for raising capital and managing relationships with the HNIs, Institutional investors and Sovereign Funds in the US and overseas including securing a $290MM investment from a single European institution for the fund.
Ms. Ulansky belongs to a unique "think tank" organized by a famous hedge fund owner along with high power investors and participates regularly in the assessment of geo political situations and their global impact.
Ms. Ulansky graduated with a Master's degree in Economics, with distinction, from Moscow State University, Russia. She holds a diploma in Art & Sculpture and a qualification of a Health Coach from the Institute of Integrative Nutrition. She is an active contributor to several publications in the US and internationally including The Huffington Post and The Hill.
Chief Operating Officer
Richard Serbin serves as Managing Director of Platform Health Ventures, a healthcare strategic and tactical consulting group as well as the Chief Operating Officer of the Gorlin Companies, LLC. Richard is a pharmacist, regulatory attorney, and patent attorney. He was Chief FDA Counsel for Revlon Corporation and Johnson & Johnson Corporation. At Johnson & Johnson he held various Senior management roles. He has served on the Board of Directors of over twenty public and private companies, including those of J&J’s, international and domestic operating companies. These were companies involved in biotechnology, dermatology, veterinary medicine, female healthcare, medical devices, photodynamic therapy, surgical and consumer products. During his career he served as the lead in taking two companies public and cofounded over ten companies. For more than a decade, he served and continues to serve as a Senior Advisor to the Swedish American Life Science Summit (SALSS), the leading invitation healthcare summit, held annually in Stockholm, Sweden.